FDA issues vouchers to 3 companies to help fast track review of potential psychedelic medications
(NEW YORK) -- The Food and Drug Administration (FDA) announced on Friday It's issuing national priority vouchers to three companies to help fast-track the review of certain psychedelic medications.The companies are studying psilocybin for treatment-resistant depression and major depressive disorder and methylone for post-traumatic stress disorder (PTSD).These vouchers mean the FDA has 60 days to review the medications for approval. "These medications have the potential to address the nation's mental health crisis, including […]